Biogen Inc.’s stock was slightly lower Tuesday, shedding early gains made after the company and Belgian partner UCB announced ...

“In partnership with Byteflies, UCB is excited to be at the forefront of next generation wearables, collaborating to evaluate the benefits of measuring patient symptoms and experiences ...

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to the class leader.

Investing.com – Belgium stocks were higher after the close ... The worst performers of the session were UCB SA (EBR:UCB), which fell 2.57% or 4.70 points to trade at 178.00 at the close.

UCB, a global biopharmaceutical company, today announced two-year data from the BE HEARD^ trials for BIMZELX® (bimekizumab-bkzx) in moderate to severe hidradenitis suppurativa (HS). Bimekizumab-bkzx, ...

UCB recently partnered with the CDD on two candidates. The Belgian biopharma company approached the CDD and, after working through the review process, reached an agreement that gives the CDD a ...